Fenretinide is under clinical development by Laurent Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Fenretinide’s likelihood of approval (LoA) and phase transition for Cystic Fibrosis took place on 06 Oct 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Fenretinide Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Fenretinide overview

Fenretinide (LAU-7b) is under development for the treatment of cystic fibrosis patients chronically infected with Pseudomonas aeruginosa. The drug candidate is administered orally as once-a-day capsule. It is an improved solid oral dosage form of fenretinide. It acts by targeting elevated levels of arachidonic acid and docosahexaenoic acid (AA/DHA).

It is under development for the treatment of Coronavirus Disease 2019 (COVID-19).

Laurent Pharmaceuticals overview

Laurent Pharmaceuticals (Laurent) is a clinical stage bio-tech company. The company’s lead product, LAU-7b (a novel oral solid form of fenretinide) is an investigational semi-synthetic retinoid addressing the unresolved inflammation, which is a leading cause of lung tissue destruction in patients with cystic fibrosis (CF). LAU-7b is a once-a-day oral pro-resolving therapy that modulates the metabolism of docosahexaenoic acid (DHA), resulting in reduced lung inflammation, improved lung physiology, and increased clearance of pulmonary infection. In addition, it also carters to Covid 19 patients with high-risk lung complications. Laurent is headquartered in Montreal, Quebec, Canada.

Quick View Fenretinide LOA Data

Report Segments
  • Innovator
Drug Name
  • Fenretinide
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
  • Respiratory
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.